我要投票 诺迪康在中草药行业中的票数:223
· 外 推 电 报 ·
2025-03-10 23:09:37 星期一

【诺迪康是哪个国家的品牌?】

诺迪康是什么牌子?「诺迪康」是 西藏诺迪康药业股份有限公司 旗下著名品牌。该品牌发源于西藏,由创始人陈达彬在1999-07-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺迪康品牌出海!通过在本页面挂载诺迪康品牌的产品链接和联系邮箱,可以提高诺迪康产品曝光!跨境电商爆单神器,目前只要100元/年哦~

西藏诺迪康药业股份有限公司是西藏雪域高原上诞生的第一家高新技术制药上市企业,于1999年7月14日创立,1999年7月21日在上海证券交易所上网交易,股票名称:西藏药业,股票代码:600211。

在各级领导的关心和支持下,公司已经发展成为一家拥有员工4000余人,总资产8.2亿元的现代化制药企业。公司累计上缴税金2亿余元,发放员工工资、福利2.2亿余元;公司主要产品诺迪康胶囊年销售额逾亿元,公司生物一类新药重组人脑利钠肽也已经上市销售。

公司拥有西藏诺迪康医药有限公司、成都诺迪康生物制药有限公司、四川诺迪康威光制药有限公司、西藏康达药业有限公司、西藏诺迪康藏药材开发有限公司、四川本草堂药业有限公司等下属子公司。

公司秉承“科学成就健康,健康成就未来”的理念,以科技兴业。在为藏药现代化不遗余力的同时,公司注巨资于生物制品和传统药品的研发,并构建了林芝种植基地和四个生产基地及覆盖全国的营销网络。产品涵盖生物制品、藏药和中药、化学药的产品系列,奠定了西藏药业持续发展的基础,其中具有自主知识产权的生物制品一类新药新活素,代表着目前国际急性心衰急救治疗药物的最高水平,填补了该领域的国内空白。

公司上市以来连续被西藏自治区认定为高新技术企业、西藏自治区农牧业龙头企业,2001年被国家科学技术部认定为国家火炬计划重点高新技术企业。2008年公司被科技部认定为创新型试点企业。公司图形商标(祥云图)经国家工商总局认定为中国驰名商标,公司产品诺迪康胶囊和十味蒂达胶囊被评为国家中药保护品种,同时,还被国家保密局、科学技术部评为秘密级国家秘密技术。

经过多年来的不懈努力,公司已成为拥有一个国家级企业技术中心、四个符合GMP规范的药品生产基地、一个符合GAP藏药材种植基地及覆盖全国的营销网络,集藏药产品、植物药产品、化学药产品、生物制品研发、生产和销售一体的现代化企业。

英文翻译:Tibet nordikang Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise born on the snow capped plateau of Tibet. It was founded on July 14, 1999 and traded on the Internet at Shanghai Stock Exchange on July 21, 1999. Its stock name is Tibet pharmaceutical, and its stock code is 600211. With the concern and support of leaders at all levels, the company has developed into a modern pharmaceutical enterprise with more than 4000 employees and total assets of 820 million yuan. The company has paid taxes of more than 200 million yuan and paid employees salaries and welfare of more than 220 million yuan; the annual sales volume of the company's main product, nordicon capsule, is more than 100 million yuan, and the company's new biological class I recombinant human brain natriuretic peptide has also been listed for sale. The company has subsidiaries including Tibet nordikang Pharmaceutical Co., Ltd., Chengdu nordikang biopharmaceutical Co., Ltd., Sichuan nordikang Weiguang Pharmaceutical Co., Ltd., Tibet Kangda Pharmaceutical Co., Ltd., Tibet nordikang Tibetan Medicine Development Co., Ltd., Sichuan bencaotang Pharmaceutical Co., Ltd. The company adheres to the concept of "science makes health, health makes future", and prospers with science and technology. While sparing no effort for the modernization of Tibetan medicine, the company has invested heavily in the research and development of biological products and traditional drugs, and has built the Linzhi planting base, four production bases and a nationwide marketing network. The products range from biological products, Tibetan medicine, traditional Chinese medicine and chemical medicine, laying the foundation for the sustainable development of Tibetan pharmaceutical industry, among which the biological products with independent intellectual property rights represent the highest level of international emergency treatment drugs for acute heart failure, and fill the domestic gap in this field. Since its listing, the company has been successively recognized as a high-tech enterprise in Tibet Autonomous Region, a leading enterprise in agriculture and animal husbandry in Tibet Autonomous Region, and a key high-tech enterprise in the national torch plan by the Ministry of science and technology of the people's Republic of China in 2001. In 2008, the company was recognized as an innovative pilot enterprise by the Ministry of science and technology. The company's graphic trademark (xiangyuntu) has been recognized as a well-known trademark in China by the State Administration of industry and commerce. The company's products, nordikang capsule and Shiweidida capsule, have been rated as the national traditional Chinese medicine protected varieties. Meanwhile, they have also been rated as the secret level national secret technology by the State Security Bureau and the Ministry of science and technology. After years of unremitting efforts, the company has become a modern enterprise with a national enterprise technology center, four GMP compliant pharmaceutical production bases, a gap compliant Tibetan medicine planting base and a nationwide marketing network, which integrates the research and development, production and sales of Tibetan medicine products, botanical medicine products, chemical medicine products and biological products.

本文链接: https://www.waitui.com/brand/0b45a7af1.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

我国科学家在抗烧结催化剂研究中取得新进展

36氪获悉,据中国科学技术大学消息,该校曾杰教授团队通过构筑纳米岛结构催化剂,攻克了甲烷干重整反应中催化剂极易烧结失活的难题。相关研究成果3月10日发表于国际学术期刊《自然∙材料》。超细金属纳米颗粒因其超高的原子利用率,在多相催化领域备受青睐。然而,在催化反应过程中,这些纳米颗粒极易受到高温等影响,从而自发聚集并导致活性降低,该过程被称作烧结。发展超细金属纳米颗粒的抗烧结策略,是催化科学领域亟待解决的关键难题。

2小时前

蔚蓝锂芯:2024年净利润4.88亿元,同比增长246.43%

36氪获悉,蔚蓝锂芯公告,公司实现营业总收入67.56亿元,同比增长29.38%;实现净利润5.44亿元,同比增长171.98%;归属于上市公司股东的净利润4.88亿元,同比增长246.43%。公司拟以2024年12月31日总股本1,152,046,537股为基数,向全体股东每10股派发现金红利0.65元(含税)。

2小时前

美股大型科技股盘前全线下跌,特斯拉跌超3%

36氪获悉,美股大型科技股盘前全线下跌,截至发稿,特斯拉、Arm跌超3%,英伟达、亚马逊、谷歌、Meta跌超2%,苹果、微软、奈飞跌超1%。

2小时前

热门中概股美股盘前普跌,B站跌超4%

36氪获悉,热门中概股美股盘前普跌,截至发稿,B站跌超4%,阿里巴巴跌超3%,京东、爱奇艺、腾讯音乐、蔚来、理想汽车、小鹏汽车跌超2%,拼多多、百度跌超1%。

2小时前

新产业:红杉聚业拟减持不超1%公司股份

36氪获悉,新产业公告,公司持股5%以上的股东天津红杉聚业股权投资合伙企业(有限合伙)计划自公告之日起15个交易日后的3个月内通过大宗交易方式减持公司股份不超过总股本的1%。若公司在减持计划实施期间发生送股、资本公积转增股本、配股等变动事项,减持股份数量进行相应调整。减持原因为自身资金需求。

2小时前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询